Optimizing Heart Rate with Ivabradine in Heart Failure with Reduced Ejection Fraction: Insights from a Post-Hoc Analysis of the SHIFT Trial
European Journal of Heart Failure · 2023
DOI: 10.1002/ejhf.2953 ↗Kurz gefasst
Editorial in der Zeitschrift European Journal of Heart Failure, 2023. Verfasst von Abdulaziz Joury. Beteiligte Einrichtung: Centre for Outcomes Research and Evaluation Research Institute of the McGill University Health Centre, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Heart Failure, Cardiovascular Agents. Die Arbeit nennt 15 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Outcomes Research and Evaluation Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
- Division of Cardiology McGill University, Health Centre McGill University, Montreal, QC, Canada.
- DREAM-CV Laboratory McGill University Health Centre McGill University, Montreal, QC, Canada.
- King Salman Heart Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Zitieren
APA
Joury, A. (2023). Optimizing Heart Rate with Ivabradine in Heart Failure with Reduced Ejection Fraction: Insights from a Post-Hoc Analysis of the SHIFT Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2953
Vancouver
Joury A. Optimizing Heart Rate with Ivabradine in Heart Failure with Reduced Ejection Fraction: Insights from a Post-Hoc Analysis of the SHIFT Trial. European Journal of Heart Failure. 2023. doi:10.1002/ejhf.2953
BibTeX
@article{Joury2023,
author = {Joury, Abdulaziz},
title = {Optimizing Heart Rate with Ivabradine in Heart Failure with Reduced Ejection Fraction: Insights from a Post-Hoc Analysis of the SHIFT Trial},
journal = {European Journal of Heart Failure},
year = {2023},
doi = {10.1002/ejhf.2953}
}
EUVIMED